1. Volume 89, Issue 2, Pages 374-385 (February 2016)
Interstitial renal fibrosis due to multiple cisplatin treatments is ameliorated by semicarbazide-sensitive amine oxidase inhibition 
Daisuke Katagiri, Yoshifumi Hamasaki, Kent Doi, Kousuke Negishi, Takeshi Sugaya, Masaomi Nangaku, Eisei Noiri 
Kidney International 
Volume 89, Issue 2, Pages (February 2016)
DOI: /ki
Copyright © 2015 International Society of Nephrology Terms and Conditions

2. Figure 1
Response to multiple CP treatments in the mouse CP–induced tubulointerstitial injury model. (a–c) Animals were administered 10 mg/kg CP three times over 4 W (0, 1, and 3 W). After exposure to CP, levels of BUN, Cre, and urinary L-FABP were significantly higher at 4 W (n = 7–8). L-FABP levels at 3 W were decreased according to the lack of CP injection at 2 W. (d) Exposure to CP caused brush-border loss at 4 W after three CP injections (bar = 50 μm). (e) To assess the cumulative CP-induced toxicity for this model, some mice (n = 6) were killed at 3 W after first CP injection. Moderate renal interstitial fibrosis was already seen at 3 W after 2 CP injections, which significantly deteriorated at 4 W after the third CP injection (bar = 50 μm). *P < Data are expressed as mean values ± SEM. BUN, blood urea nitrogen; CP, cisplatin; Cre, creatinine; L-FABP, L-type fatty acid-binding protein; MT, Masson trichrome; PAS, periodic acid-Schiff; W, weeks.
Kidney International  , DOI: ( /ki )
Copyright © 2015 International Society of Nephrology Terms and Conditions

3. Figure 2
SSAOi ameliorated kidney injury and kidney SSAO activity. L-FABP Tg mice were orally administered 2 mg/kg per day PXS-4728A (selective SSAOi) or vehicle in a volume of 10 ml/kg starting 3 W after the first CP administration (see Supplementary Figure S4 online). Double-headed arrow indicates the duration of intervention of saline (vehicle) or SSAOi treatment. (a, b, and c) Time courses of BUN and Cre. The increase in BUN and Cre at 4 W was attenuated significantly by SSAOi treatment (n = 7–8). (c) SSAOi treatment suppressed the urinary L-FABP elevation at 4 W (n = 7–8). (d) SSAO activity in whole-kidney homogenates at 4 W (n = 5–6; expressed as ratio to vehicle) was determined by fluorometry, indicating a significant suppression of SSAO activity in SSAOi-treated mice. *P < 0.05 versus vehicle, #P < 0.05 versus CP+vehicle group at 4 W. Data are expressed as mean values ± SEM. BUN, blood urea nitrogen; CP, cisplatin; Cre, creatinine; L-FABP, L-type fatty acid-binding protein; SSAOi, semicarbazide-sensitive amine oxidase inhibitor; Tg, transgenic; W, weeks.
Kidney International  , DOI: ( /ki )
Copyright © 2015 International Society of Nephrology Terms and Conditions

4. Figure 3
Morphological changes and oxidative stress induced by multiple CP administrations. (a) Formalin-fixed sections were stained with PAS and 4-HHE and 8-OHdG antibodies (bar = 50 μm). Loss of brush-border and tubular degeneration were attenuated by SSAOi treatment. Multiple CP administration caused severe accumulation of 4-HHE and 8-OHdG in damaged tubules, although this accumulation was reduced remarkably by SSAOi treatment. DHE histochemistry was performed using frozen sections to examine tubular superoxide levels. Arrows indicate DHE-positive interstitial (bar = 50 μm). (b) Semiquantitative assessment of histological damage showed a significant beneficial effect of SSAOi treatment in CP-AKI (n = 5–6). (c) 4-HHE-positive and 8-OHdG-positive areas per × 400 visual field were increased at 4 W but were reduced significantly by SSAOi treatment (n = 5–6). (d) DHE intensity ratio of CP-AKD kidney was increased significantly, which was ameliorated with SSAOi treatment (n = 5–6; intensity ratio to the vehicle). Data are expressed as mean values ± SEM. *P < 0.05 versus vehicle, #P < 0.05 versus CP+vehicle group. 4-HHE, 4-hydroxy-hexenal; 8-OHdG, 8-hydroxydeoxyguanosine; ATN, acute tubular necrosis; CP, cisplatin; DHE, dihydroethidium; PAS, periodic acid-Schiff; SSAOi, semicarbazide-sensitive amine oxidase inhibitor.
Kidney International  , DOI: ( /ki )
Copyright © 2015 International Society of Nephrology Terms and Conditions

5. Figure 4
Effect of SSAOi treatment on pro-fibrotic changes after multiple CP administrations. (a) Antifibrotic effects of SSAOi were evaluated using MT, collagen IV, and Sirius red staining. Effects of SSAOi against accumulation of macrophages after multiple CP injections were assessed using F4/80 staining (bar = 50 μm). Notable deposition of collagen I (yellow) and III (green) was found in CP-AKD mouse kidneys and was alleviated significantly with SSAOi treatment, as confirmed by Sirius red staining and polarizing microscopy. (b–d) MT-, collagen IV–, collagen type I–, and III-positive areas and F4/80-positive cells per ×400 visual field were increased at 4 W after CP initiation but were reduced significantly by SSAOi treatment (n = 5–6). Data are expressed as mean values ± SEM. *P < 0.05 versus CP+vehicle group. CP, cisplatin; MT, Masson trichrome; SSAOi, semicarbazide-sensitive amine oxidase inhibitor; W, weeks.
Kidney International  , DOI: ( /ki )
Copyright © 2015 International Society of Nephrology Terms and Conditions

6. Figure 5
Effects of SSAOi on TGF-β, VEGF, α-SMA, MCP-1, TNF-α, and IL-6 expression in the kidneys of CP-AKD mice. The mRNA expressions of (a–f) TGF-β, VEGF, α-SMA, MCP-1, TNF-α, and IL-6 in the kidney at 4 W were increased significantly by multiple CP treatments and were suppressed by SSAOi treatment (n = 5–6). 18 S rRNA in each experiment was used to normalize the relative expression of the genes of interest to 18s rRNA. Data are expressed as mean values ± SEM. *P < 0.05 versus vehicle, #P < 0.05 versus CP+vehicle. α-SMA, alpha smooth muscle actin; AKD, acute kidney diseases and disorders; CP, cisplatin; IL-6, interleukin-6; MCP-1, monocyte chemoattractant protein-1; SSAOi, semicarbazide-sensitive amine oxidase inhibitor; TGF-β, transforming growth factor-β1; TNF-α, tumor necrosis factor-alpha; VEGF, vascular endothelial growth factor.
Kidney International  , DOI: ( /ki )
Copyright © 2015 International Society of Nephrology Terms and Conditions

7. Figure 6
Lipid accumulation in CP-AKD was attenuated by SSAO inhibition. (a and b) Significant lipid accumulation in the cytoplasmic region of the outer medullary proximal tubules in the multiple CP-treated mouse kidney was attenuated with SSAOi treatment (n = 5–6; bar = 500 μm in the upper row and 50 μm in the lower row). (c) Immunohistochemical staining for L-FABP. Cytoplasmic staining of L-FABP in proximal tubules was enhanced in CP-AKD (n = 5–6, bar = 200 μm in the upper row and 50 μm in the lower row). (d) Decreased expression of L-FABP mRNA in the SSAOi-treated kidney confirmed with real-time RT-PCR analysis (n = 5–6). Data are expressed as mean values ± SEM. *P < 0.05 versus CP+vehicle group. AKD, acute kidney diseases and disorders; CP, cisplatin; L-FABP, L-type fatty acid-binding protein; SSAOi, semicarbazide-sensitive amine oxidase inhibitor. RT-PCR, reverse transcription polymerase chain reaction.
Kidney International  , DOI: ( /ki )
Copyright © 2015 International Society of Nephrology Terms and Conditions

8. Figure S1
Comparison of three doses on multiple CP treatments-induced renal injury.
Kidney International  , DOI: ( /ki )
Copyright © 2015 International Society of Nephrology Terms and Conditions

9. Figure S2
Changes in body weight, white blood cells, red blood cells, hemoglobin, and platelet counts of L-FABP Tg mice with multiple CP treatments.
Kidney International  , DOI: ( /ki )
Copyright © 2015 International Society of Nephrology Terms and Conditions

10. Figure S3
Comparison of the response to multiple CP treatments in wild-type and L-FABP Tg mice and preliminary evaluation of SSAOi alone treatment.
Kidney International  , DOI: ( /ki )
Copyright © 2015 International Society of Nephrology Terms and Conditions

11. Figure S4 Study protocol.
Kidney International  , DOI: ( /ki )
Copyright © 2015 International Society of Nephrology Terms and Conditions

12. Figure S5 Time courses of other AKI and CKD biomarkers.
Kidney International  , DOI: ( /ki )
Copyright © 2015 International Society of Nephrology Terms and Conditions